NASDAQ
08.12.25 | 21:59
14,910 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Phathom Pharmaceuticals startet Phase-2-Studie mit VOQUEZNA bei eosinophiler Ösophagitis | 4 | Investing.com Deutsch | ||
| 30.10. | Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth | 1 | Seeking Alpha | ||
| 30.10. | Phathom Pharmaceuticals stock price target raised to $20 by Guggenheim | 2 | Investing.com | ||
| 30.10. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.10. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 25.10. | Phathom: Neue Studiendaten belegen Wirksamkeit von Vonoprazan bei nächtlichen Reflux-Symptomen | 3 | Investing.com Deutsch | ||
| 25.10. | Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease | 2 | GlobeNewswire (USA) | ||
| 23.10. | Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting | 4 | GlobeNewswire (USA) | ||
| 20.10. | Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 | 4 | GlobeNewswire (USA) | ||
| 15.10. | Phathom stock remains Overweight at Cantor Fitzgerald on sales strategy shift | 1 | Investing.com | ||
| 15.10. | Strategiewechsel im Vertrieb: Cantor Fitzgerald stuft Phathom-Aktie weiter mit "Overweight" ein | 4 | Investing.com Deutsch | ||
| 09.10. | Cantor Fitzgerald reiterates Phathom stock as top pick with $29 price target | 2 | Investing.com | ||
| 09.10. | Cantor Fitzgerald bestätigt Phathom als Top-Pick mit Kursziel von 29 US-Dollar | 5 | Investing.com Deutsch | ||
| 06.10. | Phathom Pharmaceuticals Appoints Sanjeev Narula As Chief Financial And Business Officer | 2 | RTTNews | ||
| 06.10. | Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer | 1 | Investing.com | ||
| 06.10. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | Phathom Pharmaceuticals clarifies no reduction in Frazier ownership | 2 | Investing.com | ||
| 20.08. | Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing | 1 | GlobeNewswire (USA) | ||
| 08.08. | Phathom projects $165M-$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth | 2 | Seeking Alpha | ||
| 07.08. | Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat | 1 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SAREPTA THERAPEUTICS | 18,535 | -1,36 % | Sarepta Therapeutics: CEO Douglas Ingram erhält Eigenkapital-Zuteilung im Wert von 12 Millionen US-Dollar | ||
| MICROBOT MEDICAL | 2,044 | +0,99 % | Microbot Medical is a buy, Roth says | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ADAPTIMMUNE THERAPEUTICS | 0,033 | +6,45 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,766 | +1,07 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,950 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care | Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (=2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,320 | -1,82 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy | CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a... ► Artikel lesen | |
| ADICET BIO | 0,470 | +3,21 % | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 14,200 | -2,07 % | Kalvista stock price target maintained at $30 by TD Cowen amid competitor data | ||
| MARKER THERAPEUTICS | 1,070 | +9,18 % | H.C. Wainwright bestätigt Kaufempfehlung für Marker Therapeutics mit über 650 % Kurspotenzial | ||
| CARTESIAN THERAPEUTICS | 5,850 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| QUANTUM-SI | 1,455 | 0,00 % | Quantum-Si stock rating reiterated by H.C. Wainwright on Proteus potential | ||
| PROTARA THERAPEUTICS | 4,820 | -2,03 % | Protara therapeutics raises $75 million in public offering | ||
| SAGIMET BIOSCIENCES | 5,400 | +1,89 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 40,200 | -1,47 % | Crinetics Pharmaceuticals, Inc.: Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors | Initiation of trial marks milestone for Crinetics' novel nonpeptide drug conjugate platformSAN DIEGO, Dec. 03, 2025(Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 14,910 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.